Lorlatinib for treating ALK-positive advanced non-small-cell lung cancer – appraisal consultation document

In DRAFT guidance NICE does not recommend lorlatinib for ALK+ve advanced NSCLC after progression on alectinib, ceritinib or crizotinib as the most likely cost-effectiveness estimates are higher than what NICE normally considers an acceptable use of NHS resources.


National Institute for Health and Care Excellence